Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Morita, Mitsunori; Tamiya, Motohiro; Fujimoto, Daichi; Tamiya, Akihiro; Suzuki, Hidekazu; Hirano, Katsuya; Fukuda, Yasushi; Yokoyama, Toshihide; Kominami, Ryota; Kanazu, Masaki; Uchida, Junji; Hara, Satoshi; Yamashita, Shuji; Tomioka, Hiromi

doi:10.1186/s12885-020-6582-4

BMC Cancer

Article metrics
Last updated: Sat, 20 Apr 2024 14:06:52 Z

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Access & Citations

9705

Article Accesses
10

Web of Science
13

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com